GlassScriptPhysician profile
Bridget M Silva
NPI 1447342985
$3,884.57
in general payments reported to CMS, 2019-2025
24 companies · $1,820 in 2025
The $1,820 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $32.15 · 2021: $38.27 · 2022: $78.06 · 2023: $659 · 2024: $1,035 · 2025: $1,820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,514.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $813.28 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $638.58 | 2019-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $466.99 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $261.98 | 2020-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $261.51 | 2019-2025 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $237.90 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $228.56 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $142.25 | 2019-2025 | |
| Madrigal Pharmaceuticals | $141.58 | 2025 | Rezdiffra |
| Pfizer INC. | $128.75 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $124.99 | 2025 | Zenpep |
| Exact Sciences Corporation | $114.01 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $52.84 | 2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Esperion Therapeutics, INC. | $51.42 | 2024-2025 | Nexletol |
| Idorsia Pharmaceuticals US INC | $44.60 | 2022-2023 | Quviviq |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $24.44 | 2024 | Nuzyra |
| Xeris Pharmaceuticals, INC. | $22.91 | 2025 | Recorlev |
| Duchesnay USA Incorporated | $22.20 | 2019 | |
| Abbott Laboratories | $21.44 | 2023 | Freestyle Libre 2 |
| Optinose US, INC. | $20.82 | 2025 | |
| Endo Pharmaceuticals INC. | $18.77 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.86 | 2024 | Spravato |
| Currax Pharmaceuticals LLC | $14.55 | 2025 | Contrave |
| Shield Therapeutics INC | $14.34 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.